Filtered By:
Specialty: Neurology
Therapy: Statin Therapy
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 360 results found since Jan 2013.
Secondary Prevention Three and Six Years after Stroke Using the French National Insurance Healthcare System Database
Conclusions: More than one patient out of 2 do not use the optimal preventive treatment.Eur Neurol 2018;79:272 –280
Source: European Neurology - May 14, 2018 Category: Neurology Source Type: research
Lipid-Lowering Pretreatment and Outcome Following Intravenous Thrombolysis for Acute Ischaemic Stroke: A Post Hoc Analysis of the Enhanced Control of Hypertension and Thrombolysis Stroke Study Trial
Conclusions: Lipid-lowering pretreatment is not associated with adverse outcome in AIS patients treated with intravenous alteplase, whether assessed by 90-day death and disability or death alone.Cerebrovasc Dis 2018;45:213 –220
Source: Cerebrovascular Diseases - April 27, 2018 Category: Neurology Source Type: research
Effect of Statins on Survival Following Stroke in Patients With Cancer
Ye Sel Kim, Moo-Seok Park, Jun-Hwa Lee, Jong-Won Chung, Mi Ji Lee, Chi Kyung Kim, Jin-Man Jung, Kyungmi Oh, Oh Young Bang, Geong-Moon Kim, Ji-Mi Choi, Juneyoung Lee, Chin Sang Chung, Kwang Ho Lee, Woo-Keun Seo
Source: Frontiers in Neurology - April 24, 2018 Category: Neurology Source Type: research
Lipid-Lowering Agents and High HDL (High-Density Lipoprotein) Are Inversely Associated With Intracranial Aneurysm Rupture Clinical Sciences
Conclusions—Higher HDL values and the use of lipid-lowering agents are significantly inversely associated with ruptured intracranial aneurysms.
Source: Stroke - April 23, 2018 Category: Neurology Authors: Anil Can, Victor M. Castro, Dmitriy Dligach, Sean Finan, Sheng Yu, Vivian Gainer, Nancy A. Shadick, Guergana Savova, Shawn Murphy, Tianxi Cai, Scott T. Weiss, Rose Du Tags: Risk Factors, Cerebral Aneurysm Original Contributions Source Type: research
Effect of Statin Intensity on the Risk of Epilepsy After Ischaemic Stroke: Real-World Evidence from Population-Based Health Claims
ConclusionThe post-stroke use of statins after ischaemic stroke was associated with PSE risk reduction in a cDDD-dependent manner. Further clinical studies on the potential applications of statins for PSE prophylaxis, particularly among at-risk patients, are warranted.
Source: CNS Drugs - April 4, 2018 Category: Neurology Source Type: research
Role of Blood Lipids in the Development of Ischemic Stroke and its Subtypes Clinical Sciences
Conclusions—LDL cholesterol lowering is likely to prevent large artery atherosclerosis but may not prevent small artery occlusion nor cardioembolic strokes. High-density lipoprotein cholesterol elevation may lead to benefits in small artery disease prevention. Finally, triglyceride lowering may not yield benefits in ischemic stroke and its subtypes.
Source: Stroke - March 26, 2018 Category: Neurology Authors: George Hindy, Gunnar Engstrom, Susanna C. Larsson, Matthew Traylor, Hugh S. Markus, Olle Melander, Marȷu Orho–Melander Tags: Lipids and Cholesterol, Risk Factors, Ischemic Stroke Original Contributions Source Type: research
Desirable Low-Density Lipoprotein Cholesterol Levels for Preventing Stroke Recurrence Clinical Sciences
Conclusions—The composite risk of stroke and transient ischemic attack reduced in the postrandomized LDL cholesterol level of 80 to 100 mg/dL after adjusting for statin usage.Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00221104.
Source: Stroke - March 26, 2018 Category: Neurology Authors: Naohisa Hosomi, Kazuo Kitagawa, Yoji Nagai, Yoko Nakagawa, Shiro Aoki, Tomohisa Nezu, Tatsuo Kagimura, Hirofumi Maruyama, Hideki Origasa, Kazuo Minematsu, Shinichiro Uchiyama, Masayasu Matsumoto Tags: Lipids and Cholesterol, Secondary Prevention, Treatment Original Contributions Source Type: research
Letter by Scheitz et al Regarding Article, “Randomized Controlled Trial of Early Versus Delayed Statin Therapy in Patients With Acute Ischemic Stroke: ASSORT Trial (Administration of Statin on Acute Ischemic Stroke Patient)” Letter to the Editor
Source: Stroke - February 26, 2018 Category: Neurology Authors: Jan F. Scheitz, Kennedy R. Lees, Matthias Endres Tags: Cerebrovascular Disease/Stroke, Intracranial Hemorrhage, Ischemic Stroke, Neuroprotectants Letters to the Editor Source Type: research
Response by Yoshimura et al to Letter Regarding Article, “Randomized Controlled Trial of Early Versus Delayed Statin Therapy in Patients With Acute Ischemic Stroke: ASSORT Trial (Administration of Statin on Acute Ischemic Stroke Patient)” Letter to the Editor
Source: Stroke - February 26, 2018 Category: Neurology Authors: Shinichi Yoshimura, Kazutaka Uchida, Takeshi Morimoto Tags: Cerebrovascular Disease/Stroke, Ischemic Stroke, Neuroprotectants Letters to the Editor Source Type: research
Keeping Faith With Patients After Stroke or Transient Ischemic Attack
I recently recommended statin therapy to a 68-year-old patient, explaining that it would reduce his risk of a major coronary event or stroke in the next 10 years from 18% to 15%. He asked, “But how will we know if it works?” I confessed we never would because success would be an uneventful walk through good health. He was not sold.
Source: JAMA Neurology - February 5, 2018 Category: Neurology Source Type: research
Long-Term Effect of Pravastatin on Carotid Intima-Media Complex Thickness Clinical Sciences
Conclusions—The usual Japanese dose of pravastatin significantly reduced the progression of carotid IMT at 5 years in patients with noncardioembolic stroke.Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00361530.
Source: Stroke - December 22, 2017 Category: Neurology Authors: Masatoshi Koga, Kazunori Toyoda, Kazuo Minematsu, Masahiro Yasaka, Yoji Nagai, Shiro Aoki, Tomohisa Nezu, Naohisa Hosomi, Tatsuo Kagimura, Hideki Origasa, Kenji Kamiyama, Rieko Suzuki, Toshiho Ohtsuki, Hirofumi Maruyama, Kazuo Kitagawa, Shinichiro Uchiyam Tags: Risk Factors, Secondary Prevention, Ultrasound, Atherosclerosis Original Contributions Source Type: research
Statin Treatment in Patients With Intracerebral Hemorrhage Comments and Opinions
Source: Stroke - December 22, 2017 Category: Neurology Authors: Matthias Endres, Christian H. Nolte, Jan F. Scheitz Tags: Cerebrovascular Disease/Stroke, Intracranial Hemorrhage Comments and Opinions Source Type: research
Clinical Study of Intracranial and Extracranial Atherosclerotic Stenosis in Spontaneous Intracerebral Hemorrhage Patients
Nowadays, researchers had begun to focus on the use of antiplatelet and statins in patients with spontaneous intracerebral hemorrhage (sICH), but atherosclerosis treatment remains uncertain in these patients. We aimed to investigate the incidence and characteristics of intracranial and extracranial atherosclerotic stenosis in these patients and analyze its related risk factors.
Source: Journal of Stroke and Cerebrovascular Diseases - December 8, 2017 Category: Neurology Authors: Chun-Yang Zhang, Shi-Ren Huang, Si-Yang Wang, Lei Shen, Ben-Qiang Deng Source Type: research
Ultrasonographical Features Associated with Progression of Atherosclerosis in Patients with Moderate Internal Carotid Artery Stenosis
AbstractCarotid artery stenosis (CAS) is a leading cause of ischemic stroke. Plaque stabilization is a major management approach. Information about the ultrasonographical and clinical features associated with the progression of moderate internal carotid artery (ICA) stenosis (50 –69%) could assist with prognostication and risk factor modifications. We evaluated 287 patients with moderate ICA stenosis (50–69%) and subsequently evaluated them at follow-up points at 12, 24, and 36 months. Patients were divided into three groups according to the degree of ICA stenosis: pro gression (70–99%,n = 48), stable (50–69%,...
Source: Translational Stroke Research - December 1, 2017 Category: Neurology Source Type: research
Association of Osteopontin, Neopterin, and Myeloperoxidase With Stroke Risk in Patients With Prior Stroke or Transient Ischemic Attacks Clinical Sciences
Background and Purpose—Established risk factors do not fully identify patients at risk for recurrent stroke. The SPARCL trial (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) evaluated the effect of atorvastatin on stroke risk in patients with a recent stroke or transient ischemic attack and no known coronary heart disease. This analysis explored the relationships between 13 plasma biomarkers assessed at trial enrollment and the occurrence of outcome strokes.Methods—We conducted a case–cohort study of 2176 participants; 562 had outcome strokes and 1614 were selected randomly from those without outcom...
Source: Stroke - November 27, 2017 Category: Neurology Authors: Peter Ganz, Pierre Amarenco, Larry B. Goldstein, Henrik Sillesen, Weihang Bao, Gregory M. Preston, K. Michael A. Welch Tags: Biomarkers, Proteomics, Cerebrovascular Disease/Stroke Original Contributions Source Type: research
